CSF3 and AL amyloidosis: Plerixafor is a specific CXCR4 antagonist [17] approved by the FDA in 2008 in combination with Granulocyte Colony-Stimulating Factor (G-CSF) for hematopoietic stem cell mobilization and transplantation in patients receiving cytoreductive treatment for multiple myeloma or non-Hodgkins lymphoma (nHL) [18,19].